Numinus Wellness (CVE: NUMI) CEO Payton Nyquvest joined Steve Darling from Proactive to share news the company has received amendments to their licensing that will now allow the company to enhance their ability to lead psychedelics research and support the global psychedelics sector.
Nyquvest telling Proactive this change allows possession, production, assembly, sale, export, and delivery for a wide variety of psychedelics including – for the first time – Ketamine and LSD. The amendments also give Numinus Bioscience the go-ahead to pursue formulation and stability studies to assemble finished products for all approved psychedelics.